31.23 (0.76%)
As of Feb 26, 2024
Source:
We are a clinical-stage biotechnology company focused on developing the next generation of ADCs to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer patients more good days. We call this our commitment to “target a better now.”
Country | United States |
Headquarters | waltham, massachusetts |
Phone Number | (781)895-0600 |
Industry | manufacturing |
CEO | Mark J. Enyedy |
Website | www.clinicaltrials.gov |